

Fig. S4 continued




Fig. S4. In vivo activity of DLL3 CAR T cells. (**A**) The study shown in Fig. 4A was monitored for tumor growth out to 87 days. Most mice remained tumor free of SHP77 SC tumors and were re-challenge with luciferase-labeled DMS273-DLL3 tumors injected intravenously at 1x10⁵ cells/mouse on day 69. (**B**) The DMS273-DLL3 tumor burden in the study shown in Fig. S4A

was tracked by luminesce imaging and compared to tumor burden in naïve non-CAR treated mice. No detectable tumor was observed in DLL3 CAR-treated mice, while tumors did begin to grow out in CAR naïve control mice. (C) Survival curve of DMS273-DLL3 subcutaneous model demonstrating that animals who received clone 4-RSR had the best survival at the end of the study. (D) Rituximab treatment efficiently suppressed in vivo activity of DLL3 CAR T cells. DMS273-DLL3 cells were implanted subcutaneously and a single dose of CAR T cells $(3x10^6)$ CAR+ cells per animal) were injected on day 12. Starting from the day of CAR T dosing, 10 mg/kg rituximab (RTX) was dosed for 5 consecutive days via IP injection. RM One Way ANOVA was performed on tumor volume on days 16-29 with Dunnett's multiple comparisons test, p<0.05. Paired t-test was performed on tumor volume on day 32. *, p < 0.05. Error bars represent SEM, n=8. (E) Representative bioluminescence image of mouse, liver, lungs, and kidneys after IV implantation of DMS273-DLL3 tumor cells. (F) Tumor burden of individual animals in DMS273-DLL3 systemic model demonstrating only the clone 4-RSR-treated group had tumor-free animals. (G) Bioluminescence images of animals in DMS273-DLL3 systemic model. (H) H&E images demonstrating tumor cells in SHP-77 systemic model were detected in brain, liver, kidney and lung. Green circles indicate tumor cells. (I) Tumor burden of individual animals in SHP-77 systemic model demonstrating only clone 4-RSR-treated group had tumorfree animals.